Efficacy and Safety of Blinatumomab for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Systemic Review and Meta-Analysis

医学 Blinatumoab公司 内科学 入射(几何) 荟萃分析 不利影响 累积发病率 微小残留病 耐火材料(行星科学) 淋巴细胞白血病 胃肠病学 白血病 肿瘤科 移植 光学 物理 天体生物学
作者
Heng Liu,Rui Xi,Dongfeng Mao,Xiaochen Zhao,Tao Wu
出处
期刊:Clinical Lymphoma, Myeloma & Leukemia [Elsevier BV]
卷期号:23 (3): e139-e149 被引量:10
标识
DOI:10.1016/j.clml.2022.12.009
摘要

Objective The aim was to evaluate the efficacy and safety of blinatumomab monotherapy for the treatment of relapsed/refractory acute lymphoblastic leukemia (R/R B-ALL). Methods PubMed, Embase, Web of Science, and Cochrane Library were searched to collect clinical studies related to blinatumomab. The primary outcome measures were complete remission (CR), and minimal residual disease (MRD) response. Prognostic indicators included overall survival (OS) and relapse-free survival time (RFS). Grade ≥3 adverse reactions were mainly analyzed for safety, including cytokine release syndrome (CRS), neurological events and hematological toxicity. The heterogeneity was quantified by I2 statistic, which reflected the proportion of the true heterogeneity to the variance of the total effect size. Studies were considered heterogeneous if the I2 statistic was greater than 50%, and conversely, studies were homogeneous. Results A total of 18 studies involving 1,373 patients were included. The analysis results showed a CR rate of 54% (95%CI:44%-64%) and an MRD response rate of 43% (95%CI:34%-51%). The CR rate was higher in patients with bone marrow (BM) blast <50% than in patients with BM blast ≥50% (71% vs. 34%). The median OS and RFS were 8.16 months (95%CI:6.64-9.69) and 6.02 months (95%CI:4.63-7.41), respectively. For safety analysis, the incidence of grade ≥3 adverse events (AEs) was 80% (95%CI:72%-88%), the incidence of grade ≥3 neurological toxicity was 7% (95%CI:4%-11%), and the incidence of grade ≥3 CRS was 3% (95%CI:2%-5%). However, the mixture of retrospective and prospective studies led to heterogeneity to some extent in this meta-analysis. Conclusion Blinatumomab is effective in the treatment of R/R B-ALL with a controlled occurrence of AEs and a reliable safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
irisjlj发布了新的文献求助10
刚刚
1秒前
Kaz发布了新的文献求助10
1秒前
1秒前
玖文发布了新的文献求助10
1秒前
小伙子完成签到,获得积分10
2秒前
Sihan完成签到,获得积分10
5秒前
思凡完成签到,获得积分10
5秒前
5秒前
irisjlj完成签到,获得积分10
6秒前
6秒前
柔弱吉利蛋完成签到,获得积分10
6秒前
米香完成签到,获得积分10
7秒前
JamesPei应助欧维采纳,获得10
8秒前
asklepios完成签到,获得积分10
8秒前
9秒前
9秒前
water应助自由的小鸟采纳,获得10
10秒前
Kaz完成签到,获得积分20
11秒前
11秒前
Lily完成签到,获得积分10
11秒前
14秒前
Cindy发布了新的文献求助10
15秒前
LW90完成签到,获得积分10
17秒前
小二郎应助Ja采纳,获得10
17秒前
Lorene完成签到,获得积分10
17秒前
迷路宛筠完成签到 ,获得积分10
17秒前
小鱼完成签到,获得积分10
19秒前
xueluxin完成签到 ,获得积分10
20秒前
Yynnn完成签到 ,获得积分10
20秒前
悲惨的时光完成签到,获得积分10
20秒前
冷傲以珊完成签到,获得积分10
21秒前
1111111完成签到,获得积分10
21秒前
huai应助玖文采纳,获得10
22秒前
22秒前
大模型应助大神装采纳,获得10
22秒前
ilmiss发布了新的文献求助10
24秒前
Lorene发布了新的文献求助50
24秒前
24秒前
深情新之应助llly采纳,获得10
25秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969574
求助须知:如何正确求助?哪些是违规求助? 3514435
关于积分的说明 11173986
捐赠科研通 3249755
什么是DOI,文献DOI怎么找? 1794979
邀请新用户注册赠送积分活动 875537
科研通“疑难数据库(出版商)”最低求助积分说明 804844